The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
Sign Up to like & getrecommendations! Published in 2018 at "Toxicologic Pathology"
DOI: 10.1177/0192623318792537
Abstract: Short interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) are the most clinically advanced oligonucleotide-based platforms. A number of N-acetylgalactosamine (GalNAc)-conjugated siRNAs (GalNAc-siRNAs), also referred to as RNA interference (RNAi) therapeutics, are currently in various stages… read more here.
Keywords: rnai therapeutics; galnac conjugated; safety; galnac sirnas ... See more keywords